GSA Capital Partners LLP Sells 19,708 Shares of Medtronic PLC $MDT

GSA Capital Partners LLP lowered its position in Medtronic PLC (NYSE:MDT) by 87.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,924 shares of the medical technology company’s stock after selling 19,708 shares during the quarter. GSA Capital Partners LLP’s holdings in Medtronic were worth $278,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in MDT. Delos Wealth Advisors LLC purchased a new position in Medtronic in the 2nd quarter worth $27,000. Corundum Trust Company INC purchased a new position in shares of Medtronic in the third quarter worth about $27,000. Valley Wealth Managers Inc. bought a new stake in shares of Medtronic in the 3rd quarter valued at about $29,000. Steigerwald Gordon & Koch Inc. purchased a new stake in Medtronic during the 3rd quarter valued at about $33,000. Finally, Tripletail Wealth Management LLC purchased a new stake in Medtronic during the 3rd quarter valued at about $34,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the transaction, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. This trade represents a 61.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.26% of the company’s stock.

Analyst Ratings Changes

MDT has been the topic of a number of analyst reports. Truist Financial decreased their price target on Medtronic from $107.00 to $103.00 and set a “hold” rating on the stock in a research note on Wednesday, February 18th. Morgan Stanley lifted their target price on shares of Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 19th. Jefferies Financial Group reiterated a “hold” rating and set a $110.00 price target on shares of Medtronic in a report on Wednesday, November 19th. CICC Research started coverage on shares of Medtronic in a report on Friday, January 30th. They issued an “outperform” rating on the stock. Finally, The Goldman Sachs Group set a $111.00 price objective on shares of Medtronic and gave the company a “neutral” rating in a research report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $110.84.

Medtronic Stock Up 0.6%

Shares of Medtronic stock opened at $97.60 on Friday. The company has a current ratio of 2.54, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 12-month low of $79.55 and a 12-month high of $106.33. The company has a market cap of $125.31 billion, a P/E ratio of 27.19, a PEG ratio of 2.44 and a beta of 0.71. The company’s fifty day simple moving average is $98.93 and its two-hundred day simple moving average is $96.86.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The firm had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. During the same quarter in the previous year, the firm posted $1.38 EPS. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts anticipate that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were given a $0.71 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 annualized dividend and a dividend yield of 2.9%. Medtronic’s dividend payout ratio is currently 79.11%.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Positive clinical readout for Altaviva tibial neuromodulation for urinary incontinence — could support future revenue and adoption in restorative/urogynecologic portfolio. Medtronic reports positive findings for Altaviva tibial neuromod
• Positive Sentiment: Analyst coverage remains constructive: consensus “Moderate Buy” and several buy/overweight ratings and raised price targets underpin the stock’s positive bias; company also maintains a steady dividend (annualized ~$2.84, ~2.9% yield). Medtronic PLC Given Average Recommendation of “Moderate Buy” by Analysts
• Neutral Sentiment: Mixed recent share performance and valuation commentary: short-term momentum is cooling (negative returns over recent weeks/months) though 1‑year TSR remains positive — investors are watching whether earnings/guidance sustain the multiple. Assessing Medtronic (MDT) Valuation After Mixed Recent Share Performance
• Neutral Sentiment: Analysis shows MDT has underperformed the S&P 500 over the past year, which may cap sentiment despite company fundamentals — useful context for relative-performance and ETF/sector flows. How Medtronic Impacted The Healthcare Sector on The S&P 500 Chart
• Negative Sentiment: Large insider sale: EVP Harry Skip Kiil sold 52,524 shares (~$5.13M at ~$97.71) and materially reduced his position — raises some investor caution though insiders may sell for personal/liquidity reasons rather than company outlook. Medtronic EVP Harry Skip Kiil Sells 52,524 Shares

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).